Iranian Journal of Immunology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Journal Metrics

Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity

Document Type : Original Article

Authors

Department of Recombinant Proteins, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.

Abstract

Background: Trastuzumab is a humanized monoclonal antibody that targets site-specifically human epidermal growth factor-2 receptor (HER2) cell surface antigen overexpressed in approximately 20% of human breast carcinomas. Despite its positive therapeutic outcomes, a large proportion of individuals are unresponsive to the treatment with trastuzumab or develop resistance to it.
Objective: To evaluate a chemically synthesized trastuzumab-based antibody-drug conjugate (ADC) to improve the trastuzumab therapeutic index.
Methods: The current study explored the physiochemical characteristics of the trastuzumab conjugated to a cytotoxic chemotherapy agent DM1 via Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, created in our earlier study, using SDS-PAGE, UV/VIS, and RP-HPLC analyses. The antitumor effects of the ADCs were analyzed using MDA-MB-231 (HER2-negative) and SK-BR-3 (HER2-positive) cell lines utilizing in vitro cytotoxicity, viability, and binding assays. Three different formats of a HER2-targeting agent: trastuzumab, synthesized trastuzumab-MCC-DM1, and commercially available drug T-DM1 (Kadcyla®) were compared.
Results: UV-VIS spectroscopic analysis showed that the trastuzumab-MCC-DM1 conjugates, on average, entailed 2.9 DM1 payloads per trastuzumab. A free drug level of 2.5% was determined by RP-HPLC. The conjugate appeared as two bands on a reducing SDS-PAGE gel. MTT viability assay showed that conjugating trastuzumab with DM1 significantly improved the antiproliferative effects of this antibody in vitro. Importantly, the evaluations using LDH release and cell apoptosis assays confirmed that trastuzumab maintains its ability to induce cell death response while conjugating with the DM1. The binding efficiency of trastuzumab-MCC-DM1 was comparable to that of the naked trastuzumab.
Conclusion: Trastuzumab-MCC-DM1 was found effective against HER2+ tumors. The potency of this synthesized conjugate brings it closer to the commercially available T-DM1.

Keywords

References
  1. Sung, H., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021. 71(3): p. 209-249.
  2. World Health Organization. Breast cancer. 2022 January]; Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
  3. Slamon, D.J., et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. science, 1987. 235(4785): p. 177-182.
  4. Holbro, T., et al., The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences, 2003. 100(15): p. 8933-8938.
  5. Stern, D.F., Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Research, 2000. 2(3): p. 1-8.
  6. Furrer, D., et al., The human epidermal growth factor receptor 2 (HER2) as a prognostic and predictive biomarker: Molecular insights into HER2 activation and diagnostic implications. Cancer Progn, 2018.
  7. Spector, N.L. and K.L. Blackwell, Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2–positive breast cancer. Journal of Clinical Oncology, 2009. 27(34): p. 5838-5847.
  8. Fiszman, G.L. and M.A. Jasnis, Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. International journal of breast cancer, 2011.
  9. Ferraro, E., J.Z. Drago, and S. Modi, Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Research, 2021. 23(1): p. 1-11.
  10. Zahavi, D. and L. Weiner, Monoclonal antibodies in cancer therapy. Antibodies, 2020. 9(3): p. 34.
  11. Leyland-Jones, B., Trastuzumab: hopes and realities. The lancet oncology, 2002. 3(3): p. 137-144.
  12. Nahta, R. and F.J. Esteva, HER-2-targeted therapy: lessons learned and future directions. Clinical Cancer Research, 2003. 9(14): p. 5078-5084.
  13. Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer, 2015. 15(6): p. 361-370.
  14. Lambert, J.M., Drug‐conjugated antibodies for the treatment of cancer. British journal of clinical pharmacology, 2013. 76(2): p. 248-262.
  15. Drago, J.Z., S. Modi, and S. Chandarlapaty, Unlocking the potential of antibody–drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 2021. 18(6): p. 327-344.
  16. Díaz-Rodríguez, E., et al., Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers, 2022. 14(1): p. 154.
  17. Zhang, X., et al., Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antibody Therapeutics, 2022. 5(1): p. 18-29.
  18. Amiri-Kordestani, L., et al., FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clinical cancer research, 2014. 20(17): p. 4436-4441.
  19. Lambert, J.M. and R.V. Chari, Ado-trastuzumab Emtansine (T-DM1): an antibody–drug conjugate (ADC) for HER2-positive breast cancer. 2014, ACS Publications.
  20. Krop, I.E., et al., Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. The Lancet Oncology, 2017. 18(6): p. 743-754.
  21. Gobbini, E., et al., Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European journal of cancer, 2018. 96: p. 17-24.
  22. Fang, L., et al., Targeted therapy in breast cancer: what's new? Swiss medical weekly, 2011. 141(2526).
  23. Chen, Y., Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy, in Antibody-Drug Conjugates. 2013, Springer. p. 267-273.
  24. Strohl, W.R., Current progress in innovative engineered antibodies. Protein & cell, 2018. 9(1): p. 86-120.
  25. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of immunological methods, 1983. 65(1-2): p. 55-63.
  26. Dean, A.Q., et al. Targeting cancer with antibody-drug conjugates: Promises and challenges. in MAbs. 2021. Taylor & Francis.
  27. Menard, S., et al., Biologic and therapeutic role of HER2 in cancer. Oncogene, 2003. 22(42): p. 6570-6578.
  28. Bunn, P.A., et al., Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clinical cancer research, 2001. 7(10): p. 3239-3250.
  29. Iqbal, N. and N. Iqbal, Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Molecular biology international, 2014.
  30. Yan, M., et al., HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer and Metastasis Reviews, 2015. 34(1): p. 157-164.
  31. Esteva, F.J., et al., Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nature reviews Clinical oncology, 2010. 7(2): p. 98-107.
  32. Wakankar, A., et al. Analytical methods for physicochemical characterization of antibody drug conjugates. in MAbs. 2011. Taylor & Francis.
  33. Cruz, E. and V. Kayser, Synthesis and enhanced cellular uptake in vitro of anti-HER2 multifunctional gold nanoparticles. Cancers, 2019. 11(6): p. 870.
  34. Hamblett, K.J., et al., Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clinical cancer research, 2004. 10(20): p. 7063-7070.
  35. Dosio, F., P. Brusa, and L. Cattel, Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins, 2011. 3(7): p. 848-883.
  36. Shen, B.-Q., et al., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nature biotechnology, 2012. 30(2): p. 184-189.
  37. Hamann, P.R., et al., An anti-CD33 antibody− calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjugate chemistry, 2002. 13(1): p. 40-46.
  38. Kalim, M., et al., Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy. Genetics and Molecular Biology, 2020. 42.
  39. Li, Z., et al., Development of a novel EGFR-targeting antibody-drug conjugate for pancreatic cancer therapy. Targeted Oncology, 2019. 14(1): p. 93-105.
  40. Yaghoubi, S., et al., Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs). Breast Cancer, 2021. 28(1): p. 216-225.
  41. Barok, M., et al., Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer letters, 2011. 306(2): p. 171-179.
  42. Li, H., et al., An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer. Cancer biology & therapy, 2016. 17(4): p. 346-354.
Iranian Journal of Immunology
Volume 20, Issue 3
September 2023
Pages 303-315
Files
Share
How to cite
Statistics